Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Incyte Corporation
Incyte Corporation News
Incyte Corporation Quantitative Score
About Incyte Corporation
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Incyte Corporation Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Incyte Corporation Financials
Table Compare
Compare INCY metrics with: | |||
|---|---|---|---|
Earnings & Growth | INCY | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | INCY | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | INCY | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | INCY | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Incyte Corporation Income
Incyte Corporation Balance Sheet
Incyte Corporation Cash Flow
Incyte Corporation Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Buy |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Buy |
| Debt/Equity Ratio | Buy |
| Price/Earnings Ratio | Neutral |
| Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Incyte Corporation Executives
| Name | Role |
|---|---|
| Herve Hoppenot | Advisor to Chief Executive Officer & Director |
| Pablo J. Cagnoni | President and Head of Research & Development |
| Steven H. Stein | Executive VP & Chief Medical Officer |
| Vijay K. Iyengar | Executive Officer |
| Michael James Morrissey | Executive VP & Head of Global Technical Operations |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Herve Hoppenot | Advisor to Chief Executive Officer & Director | Male | 1960 | 3.6M |
| Pablo J. Cagnoni | President and Head of Research & Development | 1963 | 2.04M | |
| Steven H. Stein | Executive VP & Chief Medical Officer | 1967 | 1.56M | |
| Vijay K. Iyengar | Executive Officer | 1973 | 945.9K | |
| Michael James Morrissey | Executive VP & Head of Global Technical Operations | Male | 1964 | -- |
Incyte Corporation Insider Trades
| Date | 6 Jan |
| Name | Issa Mohamed Khairie |
| Role | EVP, Head of US Oncology |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 8264 |
| Date | 7 Jan |
| Name | Issa Mohamed Khairie |
| Role | EVP, Head of US Oncology |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 10856 |
| Date | 5 Jan |
| Name | Stein Steven H |
| Role | EVP & Chief Medical Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 15634 |
| Date | 31 Dec |
| Name | Clancy Paul J |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 241 |
| Date | 31 Dec |
| Name | HARRIGAN EDMUND |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 245 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 6 Jan | Issa Mohamed Khairie | EVP, Head of US Oncology | Disposed | F-InKind | 8264 |
| 7 Jan | Issa Mohamed Khairie | EVP, Head of US Oncology | Disposed | S-Sale | 10856 |
| 5 Jan | Stein Steven H | EVP & Chief Medical Officer | Disposed | S-Sale | 15634 |
| 31 Dec | Clancy Paul J | Director | Acquired | A-Award | 241 |
| 31 Dec | HARRIGAN EDMUND | Director | Acquired | A-Award | 245 |